Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 44INDUSTRY 26UNKNOWN 2OTHER_GOV 1NETWORK 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 36Stomach Neoplasms 19Esophageal Neoplasms 17Carcinoma, Non-Small-Cell Lung 13Colorectal Neoplasms 12Rectal Neoplasms 11Triple Negative Breast Neoplasms 9Lung Neoplasms 8Brain Neoplasms 8Small Cell Lung Carcinoma 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Neoplasm Metastasis 6Esophageal Squamous Cell Carcinoma 6Nasopharyngeal Carcinoma 5Melanoma 4Lymphoma, Extranodal NK-T-Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Recurrence 3Meningeal Carcinomatosis 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Colonic Neoplasms 3Vomiting 2Urinary Bladder Neoplasms 2Skin Diseases 2Sarcoma 2

Interventions

neratinib 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
UNKNOWN × Interventional × HER2-positive Breast Cancer × Clear all
NCT05154396 2021-12-13

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

ChineseAMS

Phase 2 Unknown
60 enrolled
Breast

HER2-positive Breast Cancer

NCT03933319 2020-07-08

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin(PLD)Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

ChineseAMS

Phase 2 Unknown
30 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡